NAS:ITCI (USA)
Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
430 East 29th Street, New York, NY, USA, 10016
Compare
Compare
Traded in other countries / regions
23I.Germany
•
ITCI.USA
Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 25.28 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 30.71 | |||||
| Beneish M-Score | -0.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -7.2 | |||||
| 3-Year FCF Growth Rate | -13.9 | |||||
| 3-Year Book Growth Rate | -4.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.08 | |||||
| 9-Day RSI | 43.82 | |||||
| 14-Day RSI | 45.85 | |||||
| 6-1 Month Momentum % | -1 | |||||
| 12-1 Month Momentum % | 87.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.17 | |||||
| Quick Ratio | 10.82 | |||||
| Cash Ratio | 9.6 | |||||
| Days Inventory | 335.9 | |||||
| Days Sales Outstanding | 70.41 | |||||
| Days Payable | 349.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.99 | |||||
| Operating Margin % | -236.52 | |||||
| Net Margin % | -234.66 | |||||
| ROE % | -54.04 | |||||
| ROA % | -47.92 | |||||
| ROIC % | -534.87 | |||||
| ROC (Joel Greenblatt) % | -774.9 | |||||
| ROCE % | -52.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.97 | |||||
| PB Ratio | 7.02 | |||||
| Price-to-Tangible-Book | 7.04 | |||||
| EV-to-EBIT | -13.67 | |||||
| EV-to-Forward-EBIT | -14.06 | |||||
| EV-to-EBITDA | -13.71 | |||||
| EV-to-Forward-EBITDA | -13.98 | |||||
| EV-to-Revenue | 32.33 | |||||
| EV-to-Forward-Revenue | 19.07 | |||||
| EV-to-FCF | -13.02 | |||||
| Price-to-Net-Current-Asset-Value | 7.26 | |||||
| Price-to-Net-Cash | 8.64 | |||||
| Earnings Yield (Greenblatt) % | -7.31 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ITCI
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 136.951 | ||
| EPS (TTM) ($) | -3.7 | ||
| Beta | 1.12 | ||
| Volatility % | 46.91 | ||
| 14-Day RSI | 45.85 | ||
| 14-Day ATR ($) | 3.210547 | ||
| 20-Day SMA ($) | 55.4655 | ||
| 12-1 Month Momentum % | 87.67 | ||
| 52-Week Range ($) | 28.445 - 66 | ||
| Shares Outstanding (Mil) | 94.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||